+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05958121

Evaluating Safety and Anti-Tumor Effects of IMA402 Alone or with Checkpoint Inhibitor in Adults With Recurrent or Refractory Solid Tumors

Led by Immatics Biotechnologies GmbH · Updated on 2026-09-01

400

Participants Needed

29

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and anti-tumor activity of a new drug called IMA402 in adults with recurrent or refractory solid tumors. This clinical trial is designed in multiple phases to find the right dose of IMA402 alone and combined with other treatments like pembrolizumab, a checkpoint inhibitor. The study aims to better understand how well IMA402 works and its effects in patients whose cancer has returned or not responded to previous treatments. The trial includes three parts Phase Ia focuses on finding the best dose by increasing or decreasing amounts of IMA402 alone or with a checkpoint inhibitor. Phase Ib extends dosing based on these results, and Phase II studies selected patient groups receiving IMA402 alone or combined with other therapies at recommended doses. Treatments involve intravenous infusions of IMA402, either alone or combined with checkpoint inhibitors, chemotherapy, monoclonal antibodies, or another investigational drug, IMA401. Participants will undergo regular assessments including safety checks, monitoring side effects, and measuring tumor response using criteria like RECIST 1.1. Researchers will collect data on adverse events, dose adjustments, and overall treatment effects over several months. The study also observes how IMA402 behaves in the body. Participants can expect ongoing evaluations throughout treatment and follow-up periods lasting up to around 40 months to understand the drugs activity and safety profile in these cancer patients.

CONDITIONS

Brief Title

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Research Team

I

Immatics Biotechnologies GmbH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here